Ligand Pharmaceuticals Incorporated (LGND)
Healthcare
Biotechnology
287.50 $
-3.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Ligand Pharmaceuticals Incorporated (LGND)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.4% of the shares are freely tradable; institutional investors hold 106.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
106.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
20Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 14.78 | 2,961,923 | +0.7 | 03/31/2026 |
| Vanguard Group Inc | 10.35 | 2,073,892 | -0.1 | 12/31/2025 |
| Vanguard Portfolio Management, LLC | 5.49 | 1,100,267 | +0.0 | 03/31/2026 |
| HHG PLC | 5.04 | 1,009,891 | +1.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.23 | 848,089 | +0.0 | 03/31/2026 |
| Amvescap Plc. | 4.11 | 823,604 | +59.5 | 03/31/2026 |
| State Street Corp | 3.89 | 778,856 | +3.7 | 03/31/2026 |
| FMR Inc | 2.97 | 596,127 | +2.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5.96 | 1,194,008 | +0.0 | 05/29/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.98 | 596,887 | +0.3 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.